"Open-label, multicenter, single arm, phase II study assessing treatment patient preference for new deferasirox formulation (film-coated tablet) compared to the reference deferasirox dispersible tablet formulation"

drug protocol number

CICL670FIC05

drug sponsor

Novartis

drug study

deferasirox

drug trial site

King Abdulaziz University Hospital (Jeddah), Hereditary Blood Disease Center (al ahsa), King Abdulaziz Medical City NG (Riyadh)

drug status

Ongoing

drug phase